Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of pomalidomide to preparation of medicine for relieving multiple sclerosis

A technology of multiple sclerosis and pomalidomide, which is applied in the application field of medicine, can solve the problems of reducing immune effects and so on

Inactive Publication Date: 2016-01-06
ZHEJIANG UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These inflammatory factors can further inhibit effector T cells and effector B cells, and reduce the immune effect; while multiple sclerosis is an autoimmune response, so far there is no report on the protective effect of pomalidomide on multiple sclerosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pomalidomide to preparation of medicine for relieving multiple sclerosis
  • Application of pomalidomide to preparation of medicine for relieving multiple sclerosis
  • Application of pomalidomide to preparation of medicine for relieving multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] 50 C57BL / 6 adult female mice were used to make EAE models. First, the mice were randomly divided into 6 groups, blank control group, EAE model group, EAE model group + pomalidomide low-dose administration group, EAE model group + pomalidomide Mid-dose administration group of idomide and EAE model group + high-dose administration group of pomalidomide, 10 rats in each group. Build EAE model: MOG first 35-55 Dissolve in sterile 1×PBS, the preparation concentration is 2mg / ml, dissolve Myco.Tuberculosis in complete Freund's adjuvant (CFA), the preparation concentration is 4mg / ml, vortex and mix. Then the two are mixed evenly by pumping and pushing back and forth through the syringe to prepare evenly dispersed immune antigens. Finally, 100 μl of the immune antigen was subcutaneously injected into the neck of the mouse, 50 μl of the immune antigen was injected subcutaneously into each of the left and right hind legs of the mouse, and 200 ng of pertussis toxin was injected in...

Embodiment 2

[0026] Spinal cords of each group on Day 16 were taken, frozen sections, and immunofluorescence. ⑴Take out the frozen section and dry it for 20 minutes; ⑵Wash 3 times with 1×PBS, 5 minutes each time; ⑶Blocking (1×PBS+5%NGS+0.3%Triton-100) for 1 hour; Preparation); (5) Wash 3 times with 1×PBS, 5 minutes each time; (6) Incubate with secondary antibody for 1 hour at room temperature in the dark (prepared with blocking buffer); (7) DAPI staining at room temperature for 5 minutes (in the dark); (8) Wash 3 times with 1×PBS, 5 minutes each time (protect from light); ⑼Seal the slide with antifade agent and store in the dark.

Embodiment 3

[0028] Paraffin-embedded the spinal cord and cross-sectioned the spinal cord with a thickness of 3 μm, and then stained with hematoxylin-eosin (Hematoxylin-Eosinstaining). ⑴ Dewax the paraffin sections with environmental transparent agent I for 15 minutes and environmental transparent agent II for 12 minutes; ⑷Stain in hematoxylin for about 2.5 minutes, rinse with tap water for about 15 minutes; ⑸Put the slices in 0.5% hydrochloric acid ethanol for color separation, see that the slices turn red, and the color is lighter; ⑹Wash for 5 minutes, ammonia water turns blue; ⑺Gradient dehydration , 70% ethanol for 2 minutes, 80% ethanol for 2 minutes, 90% ethanol for 2 minutes, 90% ethanol for 2 minutes; 95% ethanol for 2 minutes; Seal the slides after the agent is transparent.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine for treating multiple sclerosis, which is a derivative (pomalidomide) of thalidomide and is mainly applied to recurrent refractory multiple myeloma at present. Non-clinical study testifies that pomalidomide has a remarkable protection effect on EAE (Experiment Allergic Encephalomyelitis) mice with inflammatory demyelination induced by M.Tuberculosis (4 mg / ml), MOG 35-55 (2 mg / ml) and Pertussis toxin (200 ng per mouse), and can be used for treating multiple sclerosis.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to the application of chemical drug pomalidomide in the preparation of drugs for alleviating multiple sclerosis. Background technique [0002] Multiple sclerosis (Multiple Sclerosis) is an autoimmune disease characterized by inflammatory demyelination in the white matter of the central nervous system. Most patients present with recurrent neurological deficits. Multiple sclerosis occurs in young adults, and the incidence rate is higher in women than in men. Multiple sclerosis is highly common in northern Europe and North America, with an incidence rate of 50-100 / 100,000, and the incidence rate in China is also increasing year by year. Multiple sclerosis has the characteristics of rapid disease progression, relapsing-remitting type, poor treatment effect, and poor prognosis, which seriously affects the quality of life of patients. The animal model for simulating multiple sclerosis in the labo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/454A61P25/00A61P37/02
Inventor 翁勤洁胡燕王静谭笔琴王佳佳赵梦婷张卉盛荣杨波何俏军
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com